The collection of knowledge provided by all these efforts is anything but unuseful since they allow to define therapeutic pathways and targets that will bear fruit in the near future regarding clinical applications. However, population variability generally detracts from their clinical value as diagnostic or prognostic tools, although they may be used for populations at risk (18) . A way of making the obtained knowledge in this field profitable would be to specifically define which of these markers are useful in each population. Aligned with this goal is the paper by Loeff et al. (14) on gene MYO9B polymorphisms. Furthermore, their study has the added value of having been performed on a scarcely studied population from the CD genetics standpoint, as is the population of South American regions with a major Amerindian component, whereas most studies to date are focused on Caucasian populations of European descent.
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